Oberladstätter, D.; Schlimp, C.J.; Zipperle, J.; Osuchowski, M.F.; Voelckel, W.; Grottke, O.; Schöchl, H.
Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients. J. Clin. Med. 2021, 10, 3476.
https://doi.org/10.3390/jcm10163476
AMA Style
Oberladstätter D, Schlimp CJ, Zipperle J, Osuchowski MF, Voelckel W, Grottke O, Schöchl H.
Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients. Journal of Clinical Medicine. 2021; 10(16):3476.
https://doi.org/10.3390/jcm10163476
Chicago/Turabian Style
Oberladstätter, Daniel, Christoph J. Schlimp, Johannes Zipperle, Marcin F. Osuchowski, Wolfgang Voelckel, Oliver Grottke, and Herbert Schöchl.
2021. "Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients" Journal of Clinical Medicine 10, no. 16: 3476.
https://doi.org/10.3390/jcm10163476
APA Style
Oberladstätter, D., Schlimp, C. J., Zipperle, J., Osuchowski, M. F., Voelckel, W., Grottke, O., & Schöchl, H.
(2021). Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients. Journal of Clinical Medicine, 10(16), 3476.
https://doi.org/10.3390/jcm10163476
